Charles River boosts biomedical Dx testing work

Charles River Laboratories ($CRL) this week unveiled a new R&D facility focused on biomedical diagnostics testing work, highlighting ever-increasing investment in the field.

The new facility is 60,000-square-feet and based in Wilmington, MA. Since 2010, the facility housed the company's research animal diagnostics services business, Mass High Tech reports. But the expansion has also expanded capacity in areas including clinical chemistry, hematology, biomarker and assay development and immunoassay services.

The Massachusetts company said the expansion will help it boost the R&D/diagnostics services it offers both biopharmaceutical company clients, as well as academic researchers. The division's 100 employees will be able to do more work in areas, including infectious disease investigations and assay development, according to the story.

Recently, Charles River snatched up Accugenix in a $17 million deal, gaining access to that company's contract microbial testing business.

- read the release
- here's Mass High Tech's take

Like what you're reading?
Click here to get more news delivered to your inbox everyday >>

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.